05453cam a2200613Ia 4500001001300000003000600013005001700019006001900036007001500055008004100070020003600111020003300147020003600180020003300216020001800249020001500267020001800282020001500300035011100315040010500426050001000531072002500541082001500566245011300581260003400694300003600728336002600764337002600790338003600816490005900852504005100911505254000962520060603502588002604108650002204134650001904156650002504175650002304200650002204223650001904245650001404264650003604278650004804314650004904362650004504411650005104456655002204507700002504529700002004554700001604574776010504590830006004695856008404755ocn904518353OCoLC20171025092907.0m o d cr cnu---unuuu150307s2015 gw ob 001 0 eng d a9783527673643q(electronic bk.) a3527673644q(electronic bk.) a9783527673674q(electronic bk.) a3527673679q(electronic bk.) z9783527673667 z3527673660 z9783527335114 z3527335110 a(OCoLC)904518353z(OCoLC)909907512z(OCoLC)953987850z(OCoLC)960203676z(OCoLC)961625844z(OCoLC)962626284 aEBLCPbengepncEBLCPdOCLCOdRECBKdN$TdYDXCPdIDEBKdCDXdDG1dE7BdOCLCFdCOOdDEBBGdOCLCQdOHI 4aRS420 7aMEDx0710002bisacsh04a615.1922300aAntitargets and drug safety /cedited by Laszlo Urban, Vinod F. Patel and Roy J. Vaz.h[electronic resource] aWeinheim :bWiley-VCH,c2015. a1 online resource (1266 pages). atextbtxt2rdacontent acomputerbc2rdamedia aonline resourcebcr2rdacarrier1 aMethods and principles in medicinal chemistry ;vv. 66 aIncludes bibliographical references and index.0 aGeneral Concept for Target-based Safety Assessment. Side Effects of Marketed Drugs: The Utility and Pitfalls of Pharmacovigilance / Steven Whitebread, Mateusz Maciejewski, Alexander Fekete, Eugen Lounkine, László Urbán -- Prediction of Drug Side Effects / Michael J Keiser -- Translational Value of Preclinical Safety Assessment: System Organ Class (SOC) Representation of Off-Targets / Mateusz Maciejewski, Eugen Lounkine, Andreas Hartmann, Steven Whitebread, László Urbán -- Pathological Conditions Associated with the Disturbance of the 5-HT System / Daniel Hoyer -- Hepatic Side Effects. Drug-Induced Liver Injury: Clinical and Diagnostic Aspects / John R Senior -- Mechanistic Safety Biomarkers for Drug-Induced Liver Injury / Daniel J Antoine -- Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery / Frederic Moulin, Oliver Flint -- Transporters in the Liver / Bruno Stieger, Gerd A Kullak-Ublick -- Mechanistic Modeling of Drug-Induced Liver Injury (DILI) / Kyunghee Yang, Jeffrey L Woodhead, Lisl K Shoda, Yuching Yang, Paul B Watkins, Kim LR Brouwer, Brett A Howell, Scott Q Siler -- Cardiovascular Side Effects. Functional Cardiac Safety Evaluation of Novel Therapeutics / Jean-Pierre Valentin, Brian Guth, Robert L Hamlin, Pierre Lainée, Dusty Sarazan, Matt Skinner -- Safety Aspects of the Ca1.2 Channel / Berengere Dumotier, Martin Traebert -- Cardiac Sodium Current (Na1.5) / Gary Gintant -- Circulating Biomarkers for Drug-Induced Cardiotoxicity: Reverse Translation from Patients to Nonclinical Species / Gül Erdemli, Haisong Ju, Sarita Pereira -- The Mechanistic Basis of hERG Blockade and the Proarrhythmic Effects Thereof / Robert A Pearlstein, K Andrew MacCannell, Qi-Ying Hu, Ramy Farid, José S Duca -- Kinase Antitargets. Introduction to Kinase Antitargets / Mark C Munson -- Clinical and Nonclinical Adverse Effects of Kinase Inhibitors / Douglas A Keller, Richard J Brennan, Karen L Leach -- Cardiac Side Effects Associated with Kinase Proteins and Their Signaling Pathways / Roy J Vaz, Vinod F Patel -- Case Studies: Selective Inhibitors of Protein Kinases : Exploiting Demure Features / Ellen R Laird -- Examples of Clinical Translation. Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical and Models / Eric J Niesor, Andrea Greiter-Wilke, Lutz Müller -- Targets Associated with Drug-Related Suicidal Ideation and Behavior / Andreas Hartmann, Steven Whitebread, Jacques Hamon, Alexander Fekete, Christian Trendelenburg, Patrick Y Müller, László Urbán. aWith its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing.0 aPrint version record. 0aDrug development. 0aDrugsxDesign. 0aDrugsxSide effects. 0aDrug interactions. 4aDrug development. 4aDrugsxDesign. 4aMedicine. 7aMEDICALxPharmacology.2bisacsh 7aDrug development.2fast0(OCoLC)fst00898670 7aDrug interactions.2fast0(OCoLC)fst00898681 7aDrugsxDesign.2fast0(OCoLC)fst00898790 7aDrugsxSide effects.2fast0(OCoLC)fst00898912 4aElectronic books.1 aUrbán, László.1 aPatel, Vinod F.1 aVaz, Roy J.08iPrint version:aUrban, Laszlo.tAntitargets and Drug Safety.dHoboken : Wiley, ©2015z9783527335114 0aMethods and principles in medicinal chemistry ;vv. 66.40uhttp://onlinelibrary.wiley.com/book/10.1002/9783527673643zWiley Online Library